Consistently, real-time polymerase chain reaction analysis of cardiac hypertrophy markers, such as atrial natriuretic peptide, brain natriuretic peptide, and β-myosin heavy chain, manifested a significant alleviation in the presence of SMYAD compared with that in TAC-treated mice (Figure 2H). This evidence concerns the gene NPPB and cardiac hypertrophy.